A population of midbrain dopamine cells, its manufacturing method and uses
The purification of midbrain dopamine cell populations using an antibody-based cell sorting method solved the problem of impurity cells in transplanted cells, resulting in high-purity TH and EN1 positive cells. This achieved simple and low-cost cell purification with good therapeutic effects.
Patent Information
- Application Number
- CN202310823592.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-10-28
- Filing Date
- 2022-10-19
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-10-19
AI Technical Summary
In existing technologies, dopamine neurons derived from fetal or pluripotent stem cell differentiation and transplanted into the brain contain impurity cells, which may lead to side effects such as dyskinesia caused by serotonin neurons and brain region compression caused by excessive proliferation of neural stem cells.
An antibody-based cell sorting method was used, employing flow cytometry or magnetic bead sorting, to purify midbrain dopamine cell populations using antibodies targeting specific membrane proteins. This ensured that the proportion of TH and EN1-positive cells in the produced midbrain dopamine cell population was above 50%, and that the EN1-positive cells also expressed LMX1A.
High-purity TH and EN1 positive cells were obtained. The operation was simple and low-cost. The positive expression rate of any target cell marker in the cell product was not less than 50%. It showed good medical effects and few therapeutic side effects in brain transplantation experiments.
Smart Images

Figure BDA0004324239220000151 
Figure BDA0004324239220000161 
Figure BDA0004324239220000171
Abstract
Description
[0001] This case is a divisional application of the invention patent application filed on October 19, 2022, with application number 202211279544.7 and invention title "A midbrain dopamine cell population, its manufacturing method and use". Technical Field
[0002] This application relates to the field of biotherapy, specifically to a midbrain dopamine cell population, its manufacturing method, and its uses. Background Technology
[0003] Parkinson's disease is a common neurodegenerative disease in middle-aged and elderly people, primarily characterized by the progressive death of dopaminergic neurons in the midbrain. Studies have shown that transplanting fetal-derived or pluripotent stem cell-derived dopaminergic neurons into the brain can improve disease symptoms. However, these two types of cells contain various cell types, only a portion of which are true midbrain dopaminergic neurons; the remaining cells may cause various side effects. For example, serotonin neurons can cause dyskinesia, and excessive proliferation of neural stem cells can lead to brain region compression. Summary of the Invention
[0004] Based on the problems in the prior art, the problem to be solved by this application is to define a group of midbrain dopaminergic neurons with a definite fate of in vitro differentiated midbrain dopaminergic neurons. This cell group can be purified by specific surface markers to solve the problem of impurity in existing cell grafts.
[0005] This application provides:
[0006] In one embodiment, a method is provided for producing a midbrain dopamine cell population using an antibody-based cell sorting method, wherein the proportion of cells expressing TH in the produced midbrain dopamine cell population is more than 50%, and / or the proportion of cells expressing EN1 in the produced midbrain dopamine cell population is more than 50%. In yet another embodiment, the cells expressing EN1 in the produced midbrain dopamine cell population also express LMX1A.
[0007] In another specific embodiment, the cell sorting method is flow cytometry (FACS) or magnetic bead sorting (MACS).
[0008] In one specific embodiment, the antibody used in the antibody-based cell sorting method is one or more of the following antibodies capable of targeting any membrane protein in the group: CD99, VSTM2L, NRCAM, SLC16A3, CNTN6, MAP1B, LRP2, KIF21A, FLRT2, RGS2, CNRIP1, NOS1AP, SEMA3D, SLC40A1, FXYD1, CFC1, INHA, KNSTRN, KCNIP1, NAALAD2, CRYAB, RAB3C, UBE2B, B2M, LYPD3, CTTN, PLP2, ITGA6, RGS14, NOX1, S TX8, TMED1, TDG, SERINC1, DLGAP2, PPM1A, ARL17A, RALGPS2, VAMP5, MAGI2, SLITRK3, MLC1, CDH18, CLIC5, KCNJ16, MAP7, UBL3, SNCA, CD1D, PLD1, SLC24A2, NPTN, WNK2, GDE1, PMP22, DAAM1, ARL4C, FNDC5, CORO1C, RTN3, NCS1, YWHAH, MAPT, ARL8A, NSG1, SYT5, PODXL2, STXBP1, PLPPR3, UBE2QL1.
[0009] In another specific embodiment, the antibody used in the antibody-based cell sorting method is one or more antibodies capable of targeting any membrane protein in the following group: NRCAM, MAP1B, RGS2, CNRIP1, CFC1, CD99, VSTM2L, SLC16A3, INHA, NAALAD2, RAB3C, PMP22, DAAM1, CNTN6, LRP2, KCNF1, PLP2, MLC1, CDH18, CNRIP1, CLIC5, NOS1AP, SEMA3D, SLC40A1, CRYAB, LYPD3, CTTN, PLD1, ARL4C, CORO1C, PODXL2, PLPPR3.
[0010] One embodiment of the above method is provided, which further includes:
[0011] After differentiating and culturing human pluripotent stem cells to obtain midbrain dopamine precursor neural cells, an antibody-based cell sorting method was used to produce a midbrain dopamine cell population.
[0012] In yet another specific embodiment, the above method is provided, wherein,
[0013] The steps for producing midbrain dopamine cell populations using antibody-based cell sorting include:
[0014] Digestion was performed on midbrain dopaminergic neurons obtained through differentiation and culture.
[0015] Add the antibody targeting the membrane protein to the digested cells;
[0016] An antibody with affinity for the target membrane protein and linked to a fluorescent label is added to the digested cells.
[0017] Cells containing the antibody targeting the membrane protein and the fluorescently labeled antibody are washed and sorted using a flow cytometry device to obtain the midbrain dopamine cell population.
[0018] In one specific embodiment, a midbrain dopamine cell population is provided, wherein the proportion of cells expressing TH in the produced midbrain dopamine cell population is more than 50%, and the proportion of cells expressing EN1 in the produced midbrain dopamine cell population is more than 50%.
[0019] In another specific embodiment, a midbrain dopamine cell population is provided, wherein the cells expressing EN1 in the produced midbrain dopamine cell population also express LMX1A.
[0020] In another specific embodiment, the proportion of cells expressing any one of the following membrane proteins in the produced midbrain dopamine cell population is more than 50% of the total midbrain dopamine cell population: CD99, VSTM2L, NRCAM, SLC16A3, CNTN6, MAP1B, LRP2, KIF21A, FLRT2, RGS2, CNRIP1, NOS1AP, SEMA3D, SLC40A1, FXYD1, CFC1, INHA, KNSTRN, KCNIP1, NAALAD2, CRYAB, RAB3C, UBE2B, B2M, LYPD3, CTTN, PLP2, ITGA6, RGS14, NOX 1. STX8, TMED1, TDG, SERINC1, DLGAP2, PPM1A, ARL17A, RALGPS2, VAMP5, MAGI2, SLITRK3, MLC1, CDH18, CLIC5, KCNJ16, MAP7, UBL3, SNCA, CD1D, PLD1 , SLC24A2, NPTN, WNK2, GDE1, PMP22, DAAM1, ARL4C, FNDC5, CORO1C, RTN3, NCS1, YWHAH, MAPT, ARL8A, NSG1, SYT5, PODXL2, STXBP1, PLPPR3, UBE2QL1.
[0021] In another specific embodiment, the proportion of cells expressing any one of the following membrane proteins in the produced midbrain dopamine cell population is more than 50% of the total midbrain dopamine cell population: NRCAM, MAP1B, RGS2, CNRIP1, CFC1, CD99, VSTM2L, SLC16A3, INHA, NAALAD2, RAB3C, PMP22, DAAM1, CNTN6, LRP2, KCNF1, PLP2, MLC1, CDH18, CNRIP1, CLIC5, NOS1AP, SEMA3D, SLC40A1, CRYAB, LYPD3, CTTN, PLD1, ARL4C, CORO1C, PODXL2, PLPPR3.
[0022] In one specific embodiment, the aforementioned midbrain dopamine cell population is provided, wherein the midbrain dopamine cell population is prepared using the method described above.
[0023] In one embodiment, a cell preparation is provided comprising the midbrain dopamine cell population described above or produced by the method described above, and pharmaceutically acceptable adjuvants.
[0024] In yet another embodiment, the use of the midbrain dopamine cell population or the cell preparation described above in the preparation of a medicament for treating diseases related to dopamine system regulation disorders is provided.
[0025] In one specific embodiment, the disease associated with dopamine system regulation disorder is selected from the group consisting of: gene mutations related to tyrosine hydroxylase (TH), dopamine decarboxylase (AADC), dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), COMT, DRD1, DRD2, and DRD3; Parkinson's disease; schizophrenia; Tourette syndrome; attention deficit hyperactivity disorder; and depression. In yet another specific embodiment, the disease associated with dopamine system regulation disorder is Parkinson's disease.
[0026] The beneficial technical effects achieved by this application
[0027] The beneficial technical effects include: 1. High-purity cells expressing TH and EN1 were obtained using the antibody-based cell purification method of this application. The method is simple to operate, low in cost, and the positive expression rate of any target cell marker in the obtained cell product is not less than 50%; 2. The high-purity cells obtained according to the method of this application have achieved good medical results and fewer therapeutic side effects in brain transplantation experiments. Attached Figure Description
[0028] Figure 1For flow cytometry identification of dopamine neural progenitor cells differentiated from pluripotent stem cells, the proportion of EN1 was approximately 31%.
[0029] Figure 2 For immunofluorescence identification of dopamine neural progenitor cells differentiated from pluripotent stem cells, the TH ratio is approximately 15%.
[0030] Figure 3 This is a flow cytometry diagram showing the identification of dopamine neural progenitor cells after enrichment with NRCAM antibody. Staining and sorting with this antibody can enrich EN1-positive cells.
[0031] Figure 4 To identify antibody-sorted cells after adherent culture by immunofluorescence staining, the results showed that the proportion of TH+ cells could reach 71.5%, which greatly improved the purity of the cells.
[0032] Figure 5 The MAP1B antibody was used to identify dopamine neural progenitor cells differentiated from pluripotent stem cells by flow cytometry. The proportion of MAP1B+ was 35.95%.
[0033] Figure 6 This image shows immunofluorescence staining identification of dopamine neural progenitor cells after enrichment with MAP1B antibody. Using this antibody for staining and sorting, 90.5% of EN1+ cells and 95.8% of LMX1A+ cells were enriched.
[0034] Figure 7 Immunofluorescence was used to identify adherent cells after MAP1B antibody sorting and culture. The results showed that the proportion of TH+ cells could reach 80%, which greatly improved the purity of the cells.
[0035] Figure 8 For flow cytometry identification of dopamine neural progenitor cells differentiated from pluripotent stem cells, the proportion of DAAM1+ was approximately 13.28%.
[0036] Figure 9 Immunofluorescence was used to identify adherent cells after DAAM1 antibody sorting and culture. The results showed that the proportion of TH+ cells could reach 90%, which greatly improved the purity of the cells.
[0037] Figure 10 For flow cytometry identification of dopamine neural progenitor cells differentiated from pluripotent stem cells, the proportion of CD99+ was approximately 27.3%.
[0038] Figure 11 Immunofluorescence was used to identify adherent cells after CD99 antibody sorting and culture. The results showed that the proportion of TH+ cells could reach 90%, which greatly improved the purity of the cells.
[0039] Figure 12The study demonstrated the role of cells obtained after sorting with CD99 antibody in the treatment of Parkinson's disease. The results showed that, compared with the control group, cell injection significantly reduced the number of rotations in mice, and was close to that in wild-type mice, indicating that sorted cells can improve the behavioral abilities of animal models of Parkinson's disease.
[0040] Figure 13 This is the result of further culture of cells after sorting with CD99 antibody. This result shows the markers of mature cells as detected by immunofluorescence staining. Detailed Implementation
[0041] Specific embodiments of the present application will now be described in more detail with reference to the accompanying drawings. While specific embodiments of the present application are shown in the drawings, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.
[0042] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.
[0043] As used herein, "substantially free of" with respect to a particular component is used to indicate that the particular component was not intentionally formulated into the composition and / or is present only as a contaminant or in trace amounts. Therefore, the total amount of the particular component resulting from any accidental contamination of the composition is less than 0.05%, preferably less than 0.01%. Most preferably, the composition is in which the amount of the particular component is undetectable by standard analytical methods.
[0044] As used in this specification, "a" or "an" may mean one or more. As used in the claims, when used with the word "comprising," the word "a" or "an" may mean one or more.
[0045] The term “or” is used in the claims to mean “and / or” unless it is explicitly stated that it refers only to an alternative or that the alternatives are mutually exclusive, although this disclosure supports the definitions of referring only to an alternative and “and / or”. As used herein, “another” can mean at least a second or more.
[0046] Throughout this application, the term “about” is used to indicate a value that includes the inherent variation of the error of the apparatus, the method used to determine that value, or the variation that exists between subjects under study.
[0047] The methods for obtaining various biological materials described in the embodiments are merely to provide experimental methods for specific disclosure purposes and should not be construed as limiting the sources of biological materials in this application. In fact, the sources of biological materials used are wide-ranging, and any biological material that can be obtained without violating laws and ethical standards can be substituted and used according to the suggestions in the embodiments.
[0048] This application provides, in its first aspect, a method for creating a group of midbrain cells.
[0049] In one specific embodiment, a method is provided for producing a midbrain dopamine cell population using an antibody-based cell sorting method, wherein the proportion of cells expressing TH in the produced midbrain dopamine cell population is more than 50%, and / or the proportion of cells expressing EN1 in the produced midbrain dopamine cell population is more than 50%.
[0050] In the context of this application, if the proportion of cells expressing TH in the produced midbrain dopamine cell population is more than 50%, the cells expressing TH can also be identified as TH positive; if the proportion of cells expressing EN1 in the produced midbrain dopamine cell population is more than 50%, the cells expressing EN1 can also be identified as EN1 positive.
[0051] For example, the surface marker characteristics of the produced midbrain dopamine cell population can generally be expressed as follows: "More than 50% of cells are EN1 positive," "More than 60% of cells are EN1 positive," "More than 70% of cells are EN1 positive," "More than 80% of cells are EN1 positive," "More than 90% of cells are EN1 positive," "More than 50% of cells are TH positive," "More than 60% of cells are TH positive," "More than 70% of cells are TH positive," "More than 80% of cells are TH positive," "More than 90% of cells are TH positive," "More than 90% of cells are EN1 positive and more than 50% of cells are TH positive," "More than 80% of cells are EN1 positive and more than 50% of cells are TH positive," "More than 70% of cells are EN1 positive and more than 50% of cells are TH positive," "More than 6 ... The criteria for EN1 positivity and TH positivity are as follows: EN1 positive and more than 50% of cells are TH positive; EN1 positive and TH positivity is as follows: ...
[0052] In the context of this specification, "antibody-based cell sorting methods" include flow cytometry cell sorting and magnetic bead sorting. Flow cytometry cell sorting (FACS) is a technique that uses a flow cytometry cell sorting device to accurately sort fluorescently labeled single cells moving at high speed in a linear fashion. FACS uses fluorescently labeled cells, detects and receives the intensity of the fluorescent signal from the cell label through an optical system, and then uses a cell sorting system to separate the target cells corresponding to the fluorescent dye, thereby achieving the purpose of sorting specific cells from a mixed cell population. Magnetic bead sorting (MACS) involves directly or indirectly coupling specific antibodies against cell surface antigen molecules with magnetic microbeads, which then interact with the cell sample to form a complex containing immunomagnetic beads, antibodies, surface antigens, and cells. In an external magnetic field, cells bound to the immunomagnetic beads are adsorbed into the magnetic field, separating these cells from other cells that cannot bind to the magnetic beads, thus achieving the technical purpose of cell sorting. Compared to the two specific techniques used, FACS cell sorting is specific and efficient, but FACS instruments are expensive and require a large number of cell samples for sorting, while MACS is a cell sorting technology developed for small-sample, low-cost experimental research.
[0053] In yet another embodiment, the produced EN1-positive midbrain dopamine cell population is also LMX1A-positive.
[0054] For example, the overall surface marker characteristics of the produced midbrain dopamine cell population can be expressed as follows:
[0055] "Over 90% of cells are EN1 positive and over 50% of cells are LMX1A positive," "Over 80% of cells are EN1 positive and over 50% of cells are LMX1A positive," "Over 70% of cells are EN1 positive and over 50% of cells are LMX1A positive," "Over 60% of cells are EN1 positive and over 50% of cells are LMX1A positive," "Over 50% of cells are EN1 positive and over 50% of cells are LMX1A positive," "Over 50% of cells are EN1 positive and over 90% of cells are LMX1A positive," "Over 50% of cells are EN1 positive and over 80% of cells are LMX1A positive," "Over 50% of cells are..." The cell biomarkers must be positive for EN1 and at least 70% of the cells must be positive for LMX1A; at least 50% of the cells must be positive for EN1 and at least 60% of the cells must be positive for LMX1A; at least 60% of the cells must be positive for EN1 and at least 60% of the cells must be positive for LMX1A; at least 70% of the cells must be positive for EN1 and at least 70% of the cells must be positive for LMX1A; at least 80% of the cells must be positive for EN1 and at least 80% of the cells must be positive for LMX1A; or at least 90% of the cells must be positive for EN1 and at least 90% of the cells must be positive for LMX1A; and the midbrain dopamine cell population produced must also have the characteristic of being TH-positive at least 50% of the cells in addition to exhibiting the above-mentioned cell biomarker characteristics.
[0056] In the context of this specification, “TH,” “EN1,” and “LMX1A” are the names of cell surface markers, and background information on them can be found in the literature “Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors,” C R. Bye, et al., 2015. In this application, the positivity of specific surface markers in a cell population was identified; as an example, the positivity rate of EN1 was determined by flow cytometry using FACS; as an example, the positivity rate of TH was determined by immunofluorescence staining; and as an example, the positivity rate and proportion of LMX1A were determined by immunofluorescence staining.
[0057] In one specific embodiment, the antibody used in the antibody-based cell sorting method is an antibody selected from one or more membrane proteins expressed by the following group of genes: CD99, VSTM2L, NRCAM, SLC16A3, CNTN6, MAP1B, LRP2, KIF21A, FLRT2, RGS2, CNRIP1, NOS1AP, SEMA3D, SLC40A1, FXYD1, CFC1, INHA, KNSTRN, KCNIP1, NAALAD2, CRYAB, RAB3C, UBE2B, B2M, LYPD3, CTTN, PLP2, ITGA6, RGS14, NOX1, ST X8, TMED1, TDG, SERINC1, DLGAP2, PPM1A, ARL17A, RALGPS2, VAMP5, MAGI2, SLITRK3, MLC1, CDH18, CLIC5, KCNJ16, MAP7, UBL3, SNCA, CD1D, PLD1, S LC24A2, NPTN, WNK2, GDE1, PMP22, DAAM1, ARL4C, FNDC5, CORO1C, RTN3, NCS1, YWHAH, MAPT, ARL8A, NSG1, SYT5, PODXL2, STXBP1, PLPPR3, UBE2QL1.
[0058] This application does not specifically limit the source of the antibody, as long as it targets one or more of the aforementioned membrane proteins. The antibody can be purchased, or it can be produced or constructed through bioengineering, as long as it targets the aforementioned membrane proteins. When these antibodies are obtained from commercial channels, they can be purchased from companies such as R&D, Millipore, BD, Abcam, and BioLegend.
[0059] In another specific embodiment, the antibody used in the antibody-based cell sorting method is an antibody selected from one or more of the following group of gene-expressed membrane proteins: NRCAM, MAP1B, RGS2, CNRIP1, CFC1, CD99, VSTM2L, SLC16A3, INHA, NAALAD2, RAB3C, PMP22, DAAM1, CNTN6, LRP2, KCNF1, PLP2, MLC1, CDH18, CNRIP1, CLIC5, NOS1AP, SEMA3D, SLC40A1, CRYAB, LYPD3, CTTN, PLD1, ARL4C, CORO1C, PODXL2, and PLPPR3.
[0060] In the context of this specification, the membrane proteins targeted by the antibodies used to screen “TH,” “EN1,” and “LMX1A” positive cell populations were ultimately determined using bioinformatics methods and supported by experimental verification; specifically, background information on the methods used for screening membrane proteins can be found in the literature “Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors, CR. Bye, et al., 2015.” Following screening of the membrane proteins, cell sorting experiments were performed using antibodies targeting them. Unexpectedly, antibodies targeting the membrane proteins listed in Tables 2 and 3 of this application demonstrated good technical performance for cell sorting. The antibodies targeting the membrane proteins used in this application were purchased commercially from the following companies: R&D, Millipore, BD, Abcam, and BioLegend.
[0061] In one specific implementation, after differentiating and culturing human pluripotent stem cells to obtain midbrain dopamine precursor neural cells, an antibody-based cell sorting method is used to produce a midbrain dopamine cell population.
[0062] In the context of this specification, "midbrain dopamine precursor neurons" refers to differentiated cells obtained by inducing differentiation and culturing human pluripotent stem cells using methods known in the art, which have not yet undergone enrichment / purification for specific cell markers. In the context of this specification, "midbrain dopamine cell population" refers to a sorted cell population with specific pharmaceutical uses obtained by using the antibody-based cell sorting method claimed in this application to enrich / purify "midbrain dopamine precursor neurons" for specific cell markers. Methods for establishing human pluripotent stem cells can be found in the literature Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations, 2017, Stem Cell Reports.
[0063] In the proposed technical solution, "human pluripotent stem cells" are first differentiated and cultured to obtain "midbrain dopamine precursor nerve cells"; this step can be divided into cell digestion (preferably using TrypLE or acccutase digestion solution), cell counting (preferably mixing and counting in trypan blue solution), and seeding into cell differentiation medium (preferably at 2×10⁻⁶). 4 / cm 2The cells were seeded at a density in a dopamine-containing neural progenitor cell differentiation medium containing 8-20 μM Rock inhibitor (such as Y-27632) and cultured in an incubator (preferably at 37°C and 5% CO2).
[0064] Then, the "midbrain dopamine precursor neurons" obtained by the above method are subjected to an enrichment / purification process targeting specific cell markers using the antibody-based cell sorting method claimed in this application to obtain "sorted midbrain dopamine cell populations". The "antibody-based cell sorting method" here can refer to commonly used flow cytometry cell sorting procedures, specifically including cell digestion (preferably using TrypLE for digestion), adding the antibody targeting membrane proteins claimed in this application to the digested cells (preferably using PBS solution containing Y27632 to dilute the antibody, incubating at 37°C for 30 min, and mixing by pipetting every 5 min during incubation), and adding the antibody targeting membrane proteins to the cell suspension that has undergone the previous step. The antibody has affinity and is conjugated with a fluorescently labeled antibody (preferably, the obtained cell suspension is centrifuged at 1200 rpm for 3 min at room temperature, and excess antibody targeting the above membrane protein is discarded; after washing twice with PBS, a fluorescently labeled antibody with affinity for the target membrane protein is added to PBS solution containing Y27632, and incubated at 37°C in the dark for 20-60 min, mixing by pipetting every 5 min during incubation), cell washing (preferably, the above cell suspension is centrifuged at 1200 rpm for 3 min at room temperature, and excess antibody with affinity for the target membrane protein is discarded; after washing twice with PBS, an appropriate volume of PBS containing Y27632 is added to resuspend the cells, preparing 10 7 Cell suspension ( / mL, filtered through a 400-mesh / 70μm cell sieve) and flow cytometry.
[0065] Finally, the sorted midbrain dopamine cell population was further cultured to obtain a midbrain dopamine cell population suitable for specific pharmaceutical applications. This method includes cell resuspending (preferably, centrifuging the antibody-sorted cells at 1200 rpm for 3 min at room temperature, discarding the supernatant; adding cell culture medium containing Y27632 for resuspending, and taking 10 μL of the cell suspension to detect cell density and viability), and continued culturing (preferably according to the cell density detection results, at a rate of 3 × 10⁻⁶ cells / year). 6 / cm 2 (Inoculate the culture plates at the specified density and continue culturing).
[0066] The method of this application includes: antibody-based cell sorting of midbrain dopamine precursor neurons. Optionally, the method of this application includes: first differentiating and culturing human pluripotent stem cells to obtain midbrain dopamine precursor neurons, and then performing antibody-based cell sorting on the midbrain dopamine precursor neurons. Optionally, the method of this application includes: first differentiating and culturing human pluripotent stem cells to obtain midbrain dopamine precursor neurons, and then performing antibody-based cell sorting on the midbrain dopamine precursor neurons, followed by further culturing the sorted midbrain dopamine cell population to obtain a midbrain dopamine cell population suitable for a specific pharmaceutical use.
[0067] In one specific embodiment, the antibody-based cell sorting method is flow cytometry (FACS) or magnetic bead sorting (MACS), wherein the step of using FACS to produce a midbrain dopamine cell population includes:
[0068] Digestion was performed on midbrain dopaminergic neurons obtained through differentiation and culture.
[0069] Add the antibody targeting the membrane protein to the digested cells;
[0070] An antibody with affinity for the target membrane protein and linked to a fluorescent label is added to the digested cells.
[0071] Cells containing the antibody targeting the membrane protein and the fluorescently labeled antibody are washed and sorted using a flow cytometry cell sorting device.
[0072] In another specific embodiment, the midbrain dopamine cell population produced using antibody-based cell sorting is further cultured, and then cell markers can be identified using immunofluorescence staining.
[0073] In a second aspect, this application provides a population of midbrain dopamine cells.
[0074] In one embodiment, a midbrain dopamine cell population is provided, wherein more than 50% of the cells in the population are positive for TH and EN1. In yet another embodiment, the midbrain dopamine cell population is also positive for LMX1A.
[0075] In one specific embodiment, the proportion of cells expressing any one of the following membrane proteins in the produced midbrain dopamine cell population is more than 50% of the total midbrain dopamine cell population: CD99, VSTM2L, NRCAM, SLC16A3, CNTN6, MAP1B, LRP2, KIF21A, FLRT2, RGS2, CNRIP1, NOS1AP, SEMA3D, SLC40A1, FXYD1, CFC1, INHA, KNSTRN, KCNIP1, NAALAD2, CRYAB, RAB3C, UBE2B, B2M, LYPD3, CTTN, PLP2, ITGA6, RGS14, NOX1, STX8, TMED1, TDG, SERINC1, DLGAP2, P PM1A, ARL17A, RALGPS2, VAMP5, MAGI2, SLITRK3, MLC1, CDH18, CLIC5, KCNJ16, MAP7, UBL3, SNCA, CD1D, PLD1, SLC24A2, NPTN, WNK2, GDE1, PMP22, DAAM1, ARL4C, FNDC5, CORO1C, RTN3, NCS1, YWHAH, MAPT, ARL8A, NSG1, SYT5, PODXL2, STXBP1, PLPPR3, UBE2QL1; preferably, the expression ratio is 55% or higher, 60% or higher, 65% or higher, 70% or higher, 75% or higher, 80% or higher, 85% or higher, 90% or higher, 95% or higher, or higher.
[0076] In another specific embodiment, the proportion of cells expressing any one of the following membrane proteins in the produced midbrain dopamine cell population is more than 50% of the total midbrain dopamine cell population: NRCAM, MAP1B, RGS2, CNRIP1, CFC1, CD99, VSTM2L, SLC16A3, INHA, NAALAD2, RAB3C, PMP22, DAAM1, CNTN6, LRP2, KCNF1, PLP2, MLC1, CDH18, CNRIP1, CLIC5, NOS1AP, SEMA3D, SLC40A1, CRYAB, LYPD3, CTTN, PLD1, ARL4C, CORO1C, PODXL2, PLPPR3; preferably, the expression ratio is more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, or higher.
[0077] In one specific embodiment, the midbrain dopamine cell population is prepared using the aforementioned method.
[0078] This application provides a cell preparation in a third aspect.
[0079] One embodiment provides a cell preparation comprising the aforementioned midbrain dopamine cell population and pharmaceutically acceptable adjuvants.
[0080] This application provides, in its fourth aspect, the pharmaceutical use of the aforementioned cell preparations.
[0081] One specific embodiment provides the use of cell preparations in the preparation of medicaments for treating diseases associated with dopamine system dysregulation.
[0082] In another specific embodiment, the diseases associated with dopamine system regulation disorders are selected from the group consisting of: Parkinson's disease; gene mutation diseases related to tyrosine hydroxylase (TH), dopamine decarboxylase (AADC), dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT2), COMT, DRD1, DRD2, and DRD3; schizophrenia; Tourette syndrome; attention deficit hyperactivity disorder; depression; and diseases including norepinephrine deficiency, brain aging, and heart failure that can be improved by dopamine supplementation.
[0083] In the context of this specification, "Parkinson's disease" is a common neurodegenerative disease in middle-aged and elderly people, characterized primarily by bradykinesia, rigidity, and resting tremor. It often has an onset in middle age, and research suggests that its pathogenesis involves the degeneration and death of cells in the substantia nigra of the midbrain, resulting in insufficient dopamine synthesis. Treatment typically focuses on addressing dopamine deficiency, primarily through levodopa replacement therapy. The inventors of this application unexpectedly discovered that midbrain dopamine cell populations positively expressing "TH," "EN1," and "LMX1A" have a good post-implantation therapeutic effect on Parkinson's disease. In another specific embodiment, the disease related to dopamine system regulation disorder is Parkinson's disease.
[0084] Example Section
[0085] Experimental Step 1: Material Preparation
[0086] 1. Preparation of culture medium
[0087] 1. Experiment on the differentiation of pluripotent stem cells into midbrain dopamine neural progenitor cells:
[0088] (1) Preparation and concentration of each factor:
[0089] 1)LDN193189(Stemgent) solution
[0090] The working concentration is 50-500 nM. It can be stored at 4°C for two weeks.
[0091] 2) Preparation of SB431542 (R&D) solution
[0092] The working concentration is 5-50 μM. It can be stored at 4°C for two weeks.
[0093] 3) Preparation of SAG (R&D) solution
[0094] The working concentration is 0.5-10 μM. It can be stored at 4°C for two weeks.
[0095] 4) Preparation of SHH (Sonic Hedgehog) solution
[0096] The working concentration is 50-500 ng / mL. It can be stored at 4℃ for two weeks.
[0097] 5) Preparation of CHIR99021 (Stemgent) solution
[0098] Working concentration: 0.1-5 μM. For single use only.
[0099] (2) Preparation of basal culture medium N2 medium:
[0100] 49% CTS TM KnockOut TM DMEM / F-12 (Gibco) + 49% CTS TM Neurobasal (Gibco) + 1% CTS TM N2 Supplement(Gibco)+1%CTS-GlutaMAX TM -I(Gibco)
[0101] (3) Dopamine-modified neural progenitor cell differentiation culture medium 1:
[0102] N2 medium+LDN193189(100nM)+SB431542(10μM)+SHH(100ng / mL)+SAG(2μM)+CHIR99021(0.5-1.0μM);
[0103] 2. Experiment on the differentiation and maturation of midbrain dopamine progenitor cells:
[0104] (1) Preparation and use of each factor:
[0105] 1) Preparation of FGF8 (R&D) solution
[0106] The working concentration is 80-120 ng / mL. It can be stored at 4°C for two weeks.
[0107] 2) Preparation of TGFβ3 (R&D) solution
[0108] The working concentration is 0.5-1.5 ng / mL. It can be stored at 4°C for two weeks.
[0109] 3) Preparation of Ascorbic acid (AA, Sigma) solution
[0110] The working concentration is 0.1-0.5 mM. It can be stored at 4°C for two weeks.
[0111] 4) Preparation of Dibutyryl cAMP (db-cAMP, Sigma) solution
[0112] The working concentration is 0.13-0.7 mM. It can be stored at 4°C for two weeks.
[0113] 5) Preparation of BDNF (Peprotech) solution
[0114] The working concentration is 15-25 ng / mL. It can be stored at 4°C for two weeks.
[0115] 6) Preparation of GDNF (Peprotech) solution
[0116] The working concentration is 15-25 ng / mL. It can be stored at 4°C for two weeks.
[0117] (2) Preparation of basal culture medium B27 medium:
[0118] 97% CTS TM Neurobasal+2% B27-CTS TM (Gibco) +1% CTS-GlutaMAX TM -I
[0119] (3) Dopamine neuron maturation culture medium 2:
[0120] B27 medium + BDNF (20 ng / mL) + GDNF (20 ng / mL) + TGF-β3 (1 ng / mL) + AA (0.2 mM) + FGF8 (100 ng / mL), mix well and add according to the ratio, and repeatedly blow and stir;
[0121] (4) Dopamine neuron maturation culture medium 3:
[0122] B27 medium + BDNF (20 ng / mL) + GDNF (20 ng / mL) + TGF-β3 (1 ng / mL) + AA (0.2 mM) + db-cAMP (500 μM) + DAPT (10 μM), mix well and then add according to the ratio, repeatedly pipetting and mixing.
[0123] Experimental Step 2: Differentiation of Human Pluripotent Stem Cells into Midbrain Dopaminergic Neurons
[0124] 1) Method for differentiating human pluripotent stem cells into dopamine neural progenitor cells:
[0125] (1) Preparation of Vitronectin (Gibco) matrix: At room temperature, add 5-10 mL of DPBS to a 15 mL centrifuge tube, then add 50-80 μL of Vitronectin to the DPBS. Mix well by pipetting 10 times to obtain the Vitronectin matrix, which should be prepared fresh for use. Add 1 mL of the prepared matrix to each well of a six-well plate and incubate at room temperature for 1-2 hours.
[0126] (2) Human pluripotent stem cells (established in this laboratory; for specific methods and information, please refer to our laboratory's article: Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations, 2017, Stem Cell Reports) were digested into single cells using TrypLE (Gibco) or acutase (Gibco). 10 μL of the above suspension was added to 8-15 μL of trypan blue solution and mixed thoroughly. Cell counts were then performed. The Vitronectin matrix was then aspirated, and the single cells digested with TrypLE or acutase were... 4 / cm 2 The cells were seeded at a density in dopamine neural progenitor cell differentiation medium 1 containing 8-20 μM Rock inhibitor (such as Y-27632) and cultured at 37°C in a 5% CO2 incubator. The differentiation medium contained BMP inhibitors, TGF inhibitors, Wnt and SHH activators, and differentiated dopamine neural progenitor cells could be obtained after several days.
[0127] 2) Experimental method for differentiating dopamine precursor cells into mature dopamine neurons:
[0128] (1) Preparation of Vitronectin matrix: At room temperature, add 5-10 mL of DPBS to a 15 mL centrifuge tube, then add 60 μL of Vitronectin to the DPBS. Mix well by pipetting 10 times to obtain the Vitronectin matrix, which should be prepared fresh for use. Add 1 mL of the prepared matrix to each well of a six-well plate and incubate at room temperature for 1-2 hours.
[0129] (2) The aforementioned differentiated dopamine neural progenitor cells were digested into single cells using TrypLE or acccutase and seeded at a density of 5 × 10⁶ cells / year. 5 / cm 2Inoculate the cells into dopamine neuron maturation medium 2 containing a Rock inhibitor (such as Y-27632), mix well, and then incubate at 37°C in a 5% CO2 incubator.
[0130] (3) After culturing in dopamine neuron maturation medium 2 for 5-8 days, replace it with dopamine neuron maturation medium 3 and culture for more than 8 days.
[0131] Experimental Step 3: Screening Antibodies Used in Cell Sorting
[0132] Prior to the embodiments, membrane proteins targeted by antibodies for cell sorting were screened based on the target biomarkers EN1 and TH using single-cell transcriptome sequencing and bioinformatics analysis. Background information on the methods used can be found in the literature “Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors, CR. Bye, et al., 2015”. The names of the screened membrane proteins are shown in Table 1; furthermore, for the membrane proteins in Table 1, the applicant's laboratory purchased antibodies capable of targeting them from the following companies: R&D, Millipore, BD, Abcam, and BioLegend.
[0133] Table 1 shows the specific membrane proteins that can be used for cell sorting, screened using bioinformatics methods.
[0134]
[0135]
[0136]
[0137]
[0138] Experimental Step 4-1 Antibody-based Flow Cytometry Sorting Experiment
[0139] a) Cell digestion: Discard the culture supernatant of cells that need to be flow cytoscoped, wash once with PBS, add 1 mL tryple to each well for 5-8 min to digest, disperse into single cells and collect in centrifuge tubes, centrifuge at 1200 rpm at room temperature for 3 min.
[0140] b) Add the antibody targeting the above membrane protein to the digested cells: discard the culture supernatant, add PBS solution containing Y27632 to dilute the antibody, incubate at 37°C for 30 min, and mix by pipetting once every 5 min during incubation;
[0141] c) Add a fluorescently labeled antibody with affinity for the antibody targeting the membrane protein to the cell suspension that has undergone step b): Centrifuge the cell suspension at 1200 rpm for 3 min at room temperature, and discard any excess antibody targeting the membrane protein; wash twice with PBS, then add a fluorescently labeled antibody with affinity for the antibody targeting the membrane protein diluted with PBS solution containing Y27632, and incubate at 37°C in the dark for 20-60 min, mixing by pipetting every 5 min during incubation;
[0142] d) Cell washing: Centrifuge the above cell suspension at 1200 rpm for 3 min at room temperature, discard excess antibodies with affinity for the target membrane protein and fluorescently labeled; wash twice with PBS, then resuspend in an appropriate volume of PBS containing Y27632 to prepare 10 7 / mL of cell suspension, filtered through a 400-mesh / 70μm cell sieve, ready for loading into the machine;
[0143] e) Flow cytometry: Using the control group as a reference, a sorting gate is established to sort the cells that need to be sorted.
[0144] Experimental Step 4-2: Flow Cytometry Analysis Based on EN1 Antibody
[0145] a) Cell digestion: Wash the cell suspension to be analyzed once with PBS, fix with 4% PFA at room temperature for 15-30 min, and then wash 3 times with PBS. Resuspend in a mixed solution containing 2% BSA and 0.2-0.5% Triton and treat at room temperature for 2 h.
[0146] b) After centrifugation, the supernatant was discarded, the cells were resuspended in PBS solution, and an antibody targeting EN1 protein was added. The cells were incubated at 37°C for 30 min, with the mixture being pipetted and stirred every 5 min during incubation.
[0147] c) Add an antibody with affinity for the EN1 protein and a fluorescently labeled antibody to the cell suspension that has undergone step b): Centrifuge the cell suspension at 1200 rpm for 3 min at room temperature and discard the supernatant; wash twice with PBS, add an antibody with affinity for the EN1 protein and a fluorescently labeled antibody diluted with PBS solution, and incubate at 37°C in the dark for 20-60 min, mixing by pipetting every 5 min during incubation;
[0148] d) Cell washing: Centrifuge the above cell suspension at 1200 rpm for 3 min at room temperature, discard the supernatant; wash twice with PBS, then resuspend in an appropriate volume of PBS to prepare 10-1 cells. 7 / mL of cell suspension, filtered through a 400-mesh / 70μm cell sieve, ready for loading into the machine;
[0149] e) Flow cytometry: Using the control group as a reference, a sorting gate is established to analyze the cells to be analyzed.
[0150] Experimental Step 5: Cell Culture Procedure After Flow Cytometry Antibody Sorting
[0151] a) Cell resuspension: After antibody sorting in step 4, the cells were centrifuged at 1200 rpm for 3 min at room temperature, and the supernatant was discarded; the cells were resuspended in cell culture medium containing Y27632, and 10 μL of cell suspension was used to detect cell density and viability.
[0152] b) Based on the cell density test results, follow the formula 3×10 6 / cm 2 The inoculum was seeded into the culture plate at a certain density and then cultured.
[0153] The experimental procedure of step 6, immunofluorescence staining.
[0154] a) Cell seeding: Place a clean, sterile round coverslip in the center of the bottom of a 24-well cell culture dish, and seed cells after coating with vitronectin for 20-40 minutes.
[0155] b) Cell fixation: Once the cells have grown to a suitable density, discard the culture medium, wash once with PBS, fix the cells with 4% PFA at room temperature for 15-30 min, and then wash 3 times with PBS.
[0156] c) Blocking: Add 320 μL of a mixed solution of 2% BSA and 0.2-0.5% Triton to each well and block at room temperature for 2 h.
[0157] d) Add TH-targeting antibody to the digested cells: Dilute the TH-targeting antibody with a mixture of 1-3% BSA and 0.2-0.5% Triton, mix by pipetting, discard the blocking solution, add the TH-targeting antibody dilution solution, add 320 μL of TH-targeting antibody dilution solution to each well, seal with sealing film, and incubate overnight at 4°C.
[0158] e) Add a fluorescently labeled antibody with affinity for the TH-targeting antibody to the cell suspension that has undergone step d): After discarding excess TH-targeting antibody, wash twice with PBS; add 320 μL of a TH-targeting antibody with affinity diluted in a mixture of 2% BSA and 0.3% Triton to each well, and incubate at room temperature in the dark for 2 h.
[0159] f) Nucleus staining: Discard excess antibodies targeting TH and those with fluorescent labeling. Wash twice with PBS. Add 300-400 μL of Hoechst 33342 dilution buffer (1 μL Hoechst 33342 in 1 mL PBS) to each well and incubate for 15 min.
[0160] g) Mounting: Discard the Hoechst 33342 diluent and wash once with PBS; then add 10 μL of antiquenching agent to each slide, carefully pick up the glass slide with cells using a syringe needle and curved forceps, and place it on the glass slide with antiquenching agent, cell side down, to avoid air bubbles; finally, carefully dab the edges of the coverslip with colorless nail polish to fix the slide, let it air dry for 5 minutes, and then put it into the slide box.
[0161] Example 1: Cell sorting experiment using NRCAM antibody
[0162] Pluripotent stem cell-differentiated dopamine neural progenitor cells were identified by flow cytometry (see experimental steps 4-1 and 4-2 above) and immunofluorescence staining (see experimental step 6 above). The proportion of EN1 cells was approximately 31%. Figure 1 The TH ratio is approximately 15%. Figure 2 ()( Figure 1 and Figure 2 The results show the percentage of cell population markers before enrichment by antibody-based sorting. Cells were stained with NRCAM antibody (one of the antibodies obtained in experimental step 3) and then sorted by flow cytometry (see experimental step 4 for specific experimental procedures). The EN1 positive rate of the cell population enriched by flow cytometry was over 90%. Figure 3 After sorting, the cells are cultured for five days (see experimental step 5), i.e., after adherent culture, immunofluorescence staining is performed, with a TH ratio of over 70%. Figure 4 ), Figure 3 and Figure 4 The results showed the percentage of markers in the cell population after enrichment by antibody-based sorting, demonstrating that the sorted cells expressed a high proportion of EN1 and TH; the method of this application can be used for the purification of midbrain dopamine neurons.
[0163] Example 2: Cell sorting experiment using MAP1B antibody
[0164] Flow cytometry analysis of differentiated dopamine neural progenitor cells using MAP1B antibody revealed that the proportion of MAP1B+ cells reached 35.95%. Immunofluorescence analysis of the antibody-sorted MAP1B+ cells showed that, compared to the unsorted group, the proportion of EN1+ cells in MAP1B+ cells reached over 90%, and all EN1+ cells expressed LMX1A (in...). Figure 6 (See image). The sorted MAP1B+ cells were further cultured and matured, and the proportion of TH-positive cells reached over 80%. Specific results can also be found in [link to image]. Figures 5-7 .
[0165] Example 3: Cell sorting experiment using DAAM1 antibody
[0166] Flow cytometry analysis of differentiated dopamine progenitor cells using the DAAM1 antibody revealed that approximately 13% were DAAM1+ cells. Immunofluorescence analysis of the antibody-sorted DAAM1+ cells showed that the TH+ content in these cells exceeded 90%, demonstrating that the antibody can enrich dopamine neurons. Detailed results can also be found in [link to relevant documentation]. Figure 8 and Figure 9 .
[0167] Example 4-1: Cell sorting experiment using CD99 antibody
[0168] Differentiated dopamine neural progenitor cells were stained with CD99 antibody, and flow cytometry analysis revealed that approximately 27% of the cells were CD99+. Immunofluorescence analysis of the antibody-sorted CD99 cells showed that the proportion of TH+ cells in the CD99 cells reached over 90%, demonstrating that the antibody can enrich dopamine neural cells. Detailed results can also be found in [link to results]. Figure 10 and Figure 11 .
[0169] Example 4-2: Cells sorted using CD99 antibody can differentiate and mature in vitro.
[0170] CD99-negative cells, sorted with CD99 antibody, were cultured in "Dopamine Neuron Maturation Medium 3" for approximately 30 days. Immunofluorescence staining was then used to detect the expression of the mature neuron marker MAP2 and dopaminergic neuron TH. The results showed that over 90% of TH-positive cells also expressed MAP2, indicating that the sorted cells could further differentiate and mature. The results of this example... Figure 13 As shown in the image.
[0171] Example 5: Cell sorting experiment using RGS2 antibody
[0172] Differentiated dopamine neural progenitor cells were stained with RGS2 antibody, and flow cytometry analysis revealed that approximately 25% of the cells were RGS2+. Immunofluorescence analysis of the antibody-sorted RGS2 cells showed that over 80% of the RGS2 cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0173] Example 6: Cell sorting experiment using CNRIP1 antibody
[0174] Differentiated dopamine neural progenitor cells were stained with CNRIP1 antibody, and flow cytometry analysis revealed that approximately 26% of the cells were CNRIP1+. Immunofluorescence analysis of the antibody-sorted CNRIP1 cells showed that over 80% of the CNRIP1 cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0175] Example 7: Cell sorting experiment using CFC1 antibody
[0176] Differentiated dopamine neural progenitor cells were stained with CFC1 antibody, and flow cytometry analysis revealed that approximately 28% of the cells were CFC1+. Immunofluorescence analysis of the antibody-sorted CFC1 cells showed that over 80% of the CFC1 cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0177] Example 8: Cell sorting experiment using VSTM2L antibody
[0178] Differentiated dopamine neural progenitor cells were stained with VSTM2L antibody, and flow cytometry analysis revealed that approximately 26% of the cells were VSTM2L+. Immunofluorescence analysis of the antibody-sorted VSTM2L cells showed that the proportion of EN1+ cells in the VSTM2L cells reached over 85%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0179] Example 9: Cell sorting experiment using SLC16A3 antibody
[0180] Differentiated dopamine neural progenitor cells were stained with the SLC16A3 antibody. Flow cytometry analysis revealed that approximately 25% of the cells were SLC16A3+. Immunofluorescence analysis of the antibody-sorted SLC16A3 cells showed that the proportion of EN1+ cells in the SLC16A3 cells reached over 82%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0181] Example 10: Cell sorting experiment using INHA antibody
[0182] Differentiated dopamine neural progenitor cells were stained with INHA antibody, and flow cytometry analysis revealed that approximately 25% of the cells were INHA+. Immunofluorescence analysis of the antibody-sorted INHA cells showed that over 70% of the INHA cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0183] Example 11: Cell sorting experiment using NAALAD2 antibody
[0184] Differentiated dopamine neural progenitor cells were stained with NAALAD2 antibody, and flow cytometry analysis revealed that approximately 23% of the cells were NAALAD2+. Immunofluorescence analysis of the antibody-sorted NAALAD2 cells showed that over 70% of the NAALAD2 cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0185] Example 12: Cell sorting experiment using RAB3C antibody
[0186] Differentiated dopamine progenitor cells were stained with RAB3C antibody, and flow cytometry analysis revealed that approximately 23% of the cells were RAB3C+. Immunofluorescence analysis of the antibody-sorted RAB3C cells showed that the proportion of EN1+ cells in the RAB3C cells reached over 70%, demonstrating that the antibody can enrich dopamine neurons. Specific results are shown in Table 2.
[0187] Example 13: Cell sorting experiment using PMP22 antibody
[0188] Differentiated dopamine neural progenitor cells were stained with PMP22 antibody, and flow cytometry analysis revealed that approximately 26% of the cells were PMP22+. Immunofluorescence analysis of the antibody-sorted PMP22 cells showed that over 70% of the PMP22 cells were EN1+, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0189] Example 14: Cell sorting experiment using CNTN6 antibody
[0190] Differentiated dopamine neuronal progenitor cells were stained with CNTN6 antibody, and flow cytometry analysis revealed that approximately 24% of the cells were CNTN6+. Immunofluorescence analysis of the antibody-sorted CNTN6 cells showed that the proportion of EN1+ cells in CNTN6 cells reached over 76%, demonstrating that the antibody can enrich dopamine neuronal cells. Specific results are shown in Table 2.
[0191] Example 15: Cell sorting experiment using LRP2 antibody
[0192] Differentiated dopamine neural progenitor cells were stained with LRP2 antibody, and flow cytometry analysis revealed that approximately 24% of the cells were LRP2+. Immunofluorescence analysis of the antibody-sorted LRP2 cells showed that the proportion of EN1+ cells in CD99 cells reached over 73%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0193] Example 16: Cell sorting experiment using KCNF1 antibody
[0194] Differentiated dopamine neural progenitor cells were stained with KCNF1 antibody, and flow cytometry analysis revealed that approximately 23% of the cells were KCNF1+. Immunofluorescence analysis of the antibody-sorted KCNF1 cells showed that the proportion of EN1+ cells in the KCNF1 cells reached over 65%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0195] Example 17: Cell sorting experiment using PLP2 antibody
[0196] Differentiated dopamine neural progenitor cells were stained with PLP2 antibody, and flow cytometry analysis revealed that approximately 24% of the cells were PLP2+. Immunofluorescence analysis of the antibody-sorted PLP2 cells showed that the proportion of EN1+ cells in the PLP2 cells reached over 73%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0197] Example 18: Cell sorting experiment using MLC1 antibody
[0198] Differentiated dopamine neural progenitor cells were stained with MLC1 antibody, and flow cytometry analysis revealed that approximately 26% of the cells were MLC1+. Immunofluorescence analysis of the antibody-sorted MLC1 cells showed that the proportion of EN1+ cells in the MLC1 cells reached over 62%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0199] Example 19: Cell sorting experiment using CDH18 antibody
[0200] Differentiated dopamine neural progenitor cells were stained with CDH18 antibody, and flow cytometry analysis revealed that approximately 23% of the cells were CDH18+. Immunofluorescence analysis of the antibody-sorted CDH18 cells showed that the proportion of EN1+ cells in the CDH18 cells reached over 77%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0201] Example 20: Cell sorting experiment using CNRIP1 antibody
[0202] Differentiated dopamine neural progenitor cells were stained with CNRIP1 antibody, and flow cytometry analysis revealed that approximately 25% of the cells were CNRIP1+. Immunofluorescence analysis of the antibody-sorted CNRIP1 cells showed that the proportion of EN1+ cells reached over 68%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0203] Example 21: Cell sorting experiment using CLIC5 antibody
[0204] Differentiated dopamine neural progenitor cells were stained with CLIC5 antibody, and flow cytometry analysis revealed that approximately 28% of the cells were CLIC5+. Immunofluorescence analysis of the antibody-sorted CLIC5 cells showed that the proportion of EN1+ cells in the CLIC5 cells reached over 72%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0205] Example 22: Cell sorting experiment using NOS1AP antibody
[0206] Differentiated dopamine neural progenitor cells were stained with NOS1AP antibody, and flow cytometry analysis revealed that approximately 26% of the cells were NOS1AP+. Immunofluorescence analysis of the antibody-sorted NOS1AP cells showed that the proportion of EN1+ cells in the NOS1AP cells reached over 65%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0207] Example 23: Cell sorting experiment using SEMA3D antibody
[0208] Differentiated dopamine progenitor cells were stained with SEMA3D antibody, and flow cytometry analysis revealed that approximately 25% of the cells were SEMA3D+. Immunofluorescence analysis of the antibody-sorted SEMA3D cells showed that the proportion of EN1+ cells in the SEMA3D cells reached over 66%, demonstrating that the antibody can enrich dopamine neurons. Specific results are shown in Table 2.
[0209] Example 24: Cell sorting experiment using SLC40A1 antibody
[0210] Differentiated dopamine neural progenitor cells were stained with the SLC40A1 antibody, and flow cytometry analysis revealed that approximately 25% of the cells were SLC40A1+. Immunofluorescence analysis of the antibody-sorted SLC40A1 cells showed that the proportion of EN1+ cells in the SLC40A1 cells reached over 61%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0211] Example 25: Cell sorting experiment using CRYAB antibody
[0212] Differentiated dopamine neural progenitor cells were stained with CRYAB antibody, and flow cytometry analysis revealed that approximately 29% of the cells were CRYAB+. Immunofluorescence analysis of the antibody-sorted CRYAB cells showed that the proportion of EN1+ cells in the CRYAB cells reached over 76%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0213] Example 26: Cell sorting experiment using LYPD3 antibody
[0214] Differentiated dopamine neural progenitor cells were stained with LYPD3 antibody, and flow cytometry analysis revealed that approximately 29% of the cells were LYPD3+. Immunofluorescence analysis of the antibody-sorted LYPD3 cells showed that the proportion of EN1+ cells reached over 68%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0215] Example 27: Cell sorting experiment using CTTN antibody
[0216] Differentiated dopamine neural progenitor cells were stained with CTTN antibody, and flow cytometry analysis revealed that approximately 26% of the cells were CTTN+. Immunofluorescence analysis of the antibody-sorted CTTN cells showed that the proportion of EN1+ cells reached over 62%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0217] Example 28: Cell sorting experiment using PLD1 antibody
[0218] Differentiated dopamine neural progenitor cells were stained with PLD1 antibody, and flow cytometry analysis revealed that approximately 28% of the cells were PLD1+. Immunofluorescence identification of the PLD1 cells obtained by antibody sorting showed that the proportion of EN1+ cells in the PLD1 cells could reach over 70%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0219] Example 29: Cell sorting experiment using ARL4C antibody
[0220] Differentiated dopamine neural progenitor cells were stained with ARL4C antibody, and flow cytometry analysis revealed that the proportion of ARL4C+ cells was approximately 29%. Immunofluorescence identification of the ARL4C cells obtained by antibody sorting showed that the proportion of TH+ cells in the ARL4C cells could reach over 88%, proving that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0221] Example 30: Cell sorting experiment using CORO1C antibody
[0222] Differentiated dopamine neural progenitor cells were stained with CORO1C antibody, and flow cytometry analysis revealed that approximately 28% of the cells were CORO1C+. Immunofluorescence analysis of the antibody-sorted CORO1C cells showed that the proportion of TH+ cells in the CORO1C cells reached over 90%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0223] Example 31: Cell sorting experiment using PODXL2 antibody
[0224] Differentiated dopamine neural progenitor cells were stained with PODXL2 antibody, and flow cytometry analysis revealed that approximately 27% of the cells were PODXL2+. Immunofluorescence analysis of the antibody-sorted PODXL2 cells showed that the proportion of TH+ cells in the PODXL2 cells reached over 86%, demonstrating that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0225] Example 32: Cell sorting experiment using PLPPR3 antibody
[0226] Differentiated dopamine neural progenitor cells were stained with PLPPR3 antibody, and flow cytometry analysis revealed that the proportion of PLPPR3+ cells was approximately 29%. Immunofluorescence identification of PLPPR3 cells obtained by antibody sorting showed that the proportion of TH+ cells in PLPPR3 cells could reach over 81%, proving that the antibody can enrich dopamine neural cells. Specific results are shown in Table 2.
[0227] A total of 32 antibodies were used for flow cytometry sorting. After sorting, the percentage of cells expressing EN1 and TH was measured after five days of culture (positive rates were all above 50%).
[0228] Table 2 shows the results of cell sorting experiments using a total of 32 antibodies, following the experimental procedures of Examples 1-3 (cells were cultured again after 5 days of sorting).
[0229] >% NRCAM MAP1B RGS2 CNRIP1 CFC1 CD99 VSTM2L SLC16A3 EN1+ 90 90 80 80 80 80 85 82 TH+ 70 80 50 50 50 90 53 55 >% INHA NAALAD2 RAB3C PMP22 DAAM1 CNTN6 LRP2 KCNF1 EN1+ 70 70 70 70 50 76 73 65 TH+ 50 50 50 50 90 52 51 55 >% PLP2 MLC1 CDH18 CNRIP1 CLIC5 NOS1AP SEMA3D SLC40A1 EN1+ 73 62 77 68 72 65 66 61 TH+ 55 51 53 50 57 52 50 50 >% CRYAB LYPD3 CTTN PLD1 ARL4C CORO1C PODXL2 PLPPR3 EN1+ 76 68 62 70 54 62 64 64 TH+ 60 57 52 56 88 90 86 81
[0230] Table 3 shows the sorting-enrichment experiments performed on all the proteins mentioned in Table 1, and summarizes the membrane proteins that have better enrichment effects on EN1 positive cells and TH positive cells. This summary is consistent with Table 2.
[0231]
[0232]
[0233] Experiment 1: Treatment efficacy of cells sorted with CD99 antibody for Parkinson's disease
[0234] The cells used in this experiment were obtained from Example 4. To verify the role of sorted CD99 cells in the treatment of Parkinson's disease, a mouse Parkinson's disease model was established using 6-OHDA (6-hydroxydopamine) injection. Cells were then injected, with saline as a control. Five months later, an apomorphine-induced rotation test was performed to assess behavioral ability. The results showed that, compared with the control group, cell injection significantly reduced the number of rotations in mice, approaching that of wild-type mice, indicating that sorted cells can improve the behavioral ability of the Parkinson's disease animal model. Detailed results can be found in [link to specific results]. Figure 12 The modeling methods, cell transplantation, and behavioral testing methods were based on the literature Xiong et al., Human Stem Cell-Derived Neurons Repair Circuits and Restore Neural Function. 2021, Cell Stem Cell 28, 1–15.
[0235] Although the embodiments of this application have been described above in conjunction with the accompanying drawings, this application is not limited to the specific embodiments and application fields described above. The specific embodiments described above are merely illustrative and instructive, not restrictive. Those skilled in the art can make many other forms based on the guidance of this specification and without departing from the scope of protection of the claims of this application, and these are all within the scope of protection of this application.
Claims
1. A method for producing a midbrain dopamine cell population using an antibody-based cell sorting method, wherein, The midbrain dopamine cell population produced contains at least 50% cells expressing TH and at least 60% cells expressing EN1, or at least 60% cells expressing TH and at least 50% cells expressing EN1; wherein the midbrain dopamine cell population is a midbrain dopamine precursor neuronal cell. The antibody-based cell sorting method uses one or more antibodies that can target any membrane protein in the following group: CORO1C, PODXL2, PLPPR3. The membrane protein is the membrane protein targeted by the antibody used for cell sorting, which is selected based on the target markers EN1 and TH.
2. The method according to claim 1, wherein, The produced midbrain dopamine cell population contains more than 80% cells expressing TH and more than 60% cells expressing EN1. These midbrain dopamine cell populations are midbrain dopamine precursor neurons. The antibody used in the antibody-based cell sorting method targets the CORO1C membrane protein, which is the membrane protein targeted by the antibody used for cell sorting, selected based on the target markers EN1 and TH.
3. The method according to claim 1 or 2, wherein, The midbrain dopamine cell population produced also contains cells that express EN1 and LMX1A.
4. The method according to claim 1 or 2, wherein, The cell sorting method is either flow cytometry (FACS) or magnetic bead sorting (MACS).
5. The method according to claim 1 or 2, further comprising: After differentiating and culturing human pluripotent stem cells to obtain midbrain dopamine precursor neural cells, an antibody-based cell sorting method was used to produce a midbrain dopamine cell population.
6. The method according to claim 5, wherein, The steps for producing midbrain dopamine cell populations using antibody-based cell sorting include: Digestion was performed on midbrain dopaminergic neurons obtained through differentiation and culture. Add the antibody targeting the membrane protein to the digested cells; An antibody with affinity for the target membrane protein and linked to a fluorescent label is added to the digested cells. Cells containing the antibody targeting the membrane protein and the fluorescently labeled antibody are washed and sorted using a flow cytometry device to obtain the midbrain dopamine cell population.
Citation Information
Patent Citations
Method for the generation of a cell composition ventral midbrain dopaminergic progenitor cells
US20210079344A1
Methods of generating and isolating midbrain dopamine neurons
WO2021042027A1
